Obermatt
See Similar Stocks →

Pliant Therapeutics

NSQ:PLRX · US7291391057
PharmaceuticalsSmall

360

41
Medium confidence — indicative
EV / EBIT87
Price / Owner Earnings50
Owner Earnings Yield1
Dividend Yield1
Price/Sales7
Price/Book70
Return on Capital22
Cash Return on Capital12
Return on Equity17
Profit margins—

Cash truth not applicable for financial companies.

Sales growth—
Profit growth31
Reinvestment76
Price momentum12
Debt load50
Refinancing18
Debt Payback1
Liquidity8
Analyst ratings7
Opinion Changes50
Price Target Upside70
Market mood17
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Pliant Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 4/5 components.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2015
Employees95
Websitepliantrx.com
ISINUS7291391057
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Chronic DiseasesPulmonologyHepatologyOncologyBiotechnologyHealth CareHealth DiagnosticsPharmaceuticalRecruitingTherapeutics

Description

Pliant Therapeutics, Inc. (Pliant) operates as a late-stage biopharmaceutical company focuses on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The company’s initial focus is on treating fibrosis by in…

Analysis

Middle-of-the-road

Pliant Therapeutics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is mixed; the safety picture is adequate. The company scores 2/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
9
2023202420252026

All-time high

20

Jan 2023

All-time low

1

Mar 2026

Average rank

9

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
7
1
1
1
Price/Earnings
47
14
14
14
Price/Book
70
83
39
54
Dividend Yield
1
1
1
1
Value (overall)
57
30
10
19

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Pliant Therapeutics with its peers
Rapport Therapeutics
NMQ:RAPP
13
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Relmada Therapeutics
NAQ:RLMD
—
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
EyePoint
NMQ:EYPT
34
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
AnaptysBio
NSQ:ANAB
44
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Trevi Therapeutics
NMQ:TRVI
96
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
LB Pharmaceuticals
NMQ:LBRX
79
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →